Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1749

Novel Approaches for HIV Vaccines that Elicit Neutralizing Antibodies: Stable gp140 Trimers

Inventors: Stephen Harrison, Bing Chen, Dan Barouch, Joseph Nkolola, Michael Seaman

Invention Types: Therapeutics

Research Areas: Infectious Disease

Keywords: Vaccine

For More Information Contact:  Caron, Connie

 

Invention Description:

HIV/AIDS is a major global epidemic problem affecting 0.8% of worldwide population and causing ~2 million deaths each year in the entire world. As of the end of 2009, approximately 36 million persons worldwide were living with HIV/AIDS, of which 2.5 million were newly infected during the year. A successful HIV vaccine has been elusive, due to the failure to produce an immuogen that elicits the robust production of protective, neutralizing antibodies in the recipient.||

Drs. Chen and Harrison developed a protein structure-based paradigm to vaccine design, incorporating the understanding of the dynamic changes in protein structure that occur on viral entry into the cell.


One major hurdle in the development of an immunogen for an HIV vaccine has been the need to present the viral envelop proteins in their native trimeric conformation. In collaboration with investigators from Beth Israel Deaconess Medical Center, the inventors screened HIV gp140 proteins from a wide number of viral isolates and identified protein variants that form stable trimers and elicit strongly neutralizing antibodies in animal models.

Applications:

Immunogens for an HIV vaccine that elicit robust neutralizing antibody production.

Competitive Advantages:

Current AIDS treatment (HAART) is expensive and offers no cure. A preventive vaccine is greatly needed, in particular for developing countries where costly medicines are often unavailable and disease transmission continues unchecked. Currently, no one has successfully developed an HIV vaccine.

Business Opportunity:

• Exclusive or non-exclusive license to a company with existing HIV vaccine development pipeline ||
• Sponsored Research

Key Publications: Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, Lynch DM, La Porte A, Simmons NL, Bradley R, Montefiori DC, Seaman MS, Chen B, Barouch DH. J Virol. 2010 Apr;84(7):3270-9. PMID: 20053749
http://www.ncbi.nlm.nih.gov/pubmed/20053749

IPStatus: Pat. Pend.